Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20953292 | 0.90 | NAMPT (0.77) | NAMPTHDAC3HDAC1HDAC2ROCK2 | |
| SCHEMBL22419527 | 0.89 | NAMPT (0.70) | NAMPTHDAC3HDAC1HDAC2 | |
| SCHEMBL22419555 | 0.86 | NAMPT (0.74) | NAMPTHDAC3HDAC1HDAC2ROCK2 | |
| SCHEMBL22419484 | 0.86 | NAMPT (0.78) | NAMPTHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL22419482 | 0.86 | NAMPT (0.74) | NAMPTHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL22419522 | 0.84 | NAMPT (0.74) | NAMPTHDAC3HDAC1HDAC2GAA | |
| SCHEMBL22419450 | 0.83 | NAMPT (0.70) | NAMPTHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL15530777 | 0.83 | NAMPT (0.66) | NAMPT | |
| SCHEMBL22419489 | 0.83 | NAMPT (0.72) | NAMPTHDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL173499 | 0.82 | NAMPT (0.76) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885HDAC3 89/4885HDAC1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.